0R2M 주식 개요 는 전 세계적으로 다양한 질병 치료를 위한 의약품을 발견, 발명, 개발, 제조 및 상업화하는 회사입니다. 자세한 내용
보상 위험 분석 위험 검사에서 0R2M 에 대한 위험이 감지되지 않았습니다.
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
Regeneron Pharmaceuticals, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Regeneron Pharmaceuticals 과거 주가 현재 주가 US$674.74 52주 최고치 US$1,210.92 52주 최저치 US$665.34 베타 0.094 1개월 변경 -5.37% 3개월 변경 사항 -19.86% 1년 변경 사항 -28.56% 3년 변화 8.06% 5년 변화 73.44% IPO 이후 변화 85.17%
최근 뉴스 및 업데이트
Regeneron Pharmaceuticals, Inc. Announces Adjuvant Libtayo (Cemiplimab) Significantly Improves Disease-Free Survival After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 Trial Jan 14
Gainey Mckenna & Egleston Files Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc Jan 09
Regeneron Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 04, 2025 Jan 08
Regeneron Pharmaceuticals, Inc. to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-Concept Results Dec 19
Regeneron Pharmaceuticals, Inc. Announces EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion Dec 18
Odronextamab Ash Presentations Underscore Impressive Potential in Early Lines of Treatment and Additional Types of Lymphoma Dec 10 더 많은 업데이트 보기
Regeneron Pharmaceuticals, Inc. Announces Adjuvant Libtayo (Cemiplimab) Significantly Improves Disease-Free Survival After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 Trial Jan 14
Gainey Mckenna & Egleston Files Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc Jan 09
Regeneron Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 04, 2025 Jan 08
Regeneron Pharmaceuticals, Inc. to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-Concept Results Dec 19
Regeneron Pharmaceuticals, Inc. Announces EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion Dec 18
Odronextamab Ash Presentations Underscore Impressive Potential in Early Lines of Treatment and Additional Types of Lymphoma Dec 10
Regeneron Pharmaceuticals, Inc. Announces that Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieve Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab Dec 09 Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®? Nov 15
Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting Nov 13 Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis Nov 07
Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023) Nov 01
Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem Oct 19
Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China Sep 29 Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China Sep 28
Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Sep 27 Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps Sep 14
Senior VP of Finance & CFO recently sold US$6.4m worth of stock Aug 30
Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Aug 27
Regeneron Provides Update on Biologics License Application for Linvoseltamab Aug 21
Insider recently sold US$5.6m worth of stock Aug 13
Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023) Aug 02 Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD Jul 04
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Jun 29
Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jun 28
Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine Jun 27
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma Jun 18 Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation Jun 01
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28) May 24 Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine May 22
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent May 15
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks May 09
New minor risk - Shareholder dilution May 04 Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares. May 03
First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023) May 03
Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma Apr 10 Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million. Apr 01
Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab Mar 27
Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol Mar 11
Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg Mar 09 Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation Feb 24
Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review Feb 23 Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria Feb 16
Insider recently sold US$7.6m worth of stock Feb 09
Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022) Feb 04
Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma Feb 03 Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024 Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis Jan 26
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab) Jan 17
Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024 Jan 06
Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes Dec 12
Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma Dec 08
Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023 Dec 07
Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial Nov 29
Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial Nov 28
Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022) Nov 02
Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg Nov 02
Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss Oct 28 주주 수익률 0R2M GB Biotechs GB 마켓 7D -1.0% 5.1% 2.0% 1Y -28.6% -17.6% 10.8%
전체 주주 수익률 보기
수익률 대 산업: 0R2M 지난 1년 동안 -17.6 %를 반환한 UK Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 0R2M 지난 1년 동안 10.8 %를 반환한 UK 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 0R2M's price volatile compared to industry and market? 0R2M volatility 0R2M Average Weekly Movement 3.4% Biotechs Industry Average Movement 9.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 2.7%
안정적인 주가: 0R2M 지난 3개월 동안 UK 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: 0R2M 의 주간 변동성 ( 3% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 는 전 세계적으로 다양한 질병을 치료하기 위한 의약품을 발견, 발명, 개발, 제조 및 상업화합니다. 주요 제품으로는 습성 연령 관련 황반변성 및 당뇨병성 황반부종, 근시성 맥락막 신생혈관, 당뇨병성 망막증, 신생혈관 녹내장, 미숙아 망막증을 치료하는 아이리아 주사가 있습니다. 또한 성인 및 소아 아토피 피부염 및 천식 치료제 듀픽센트 주사, 전이성 또는 국소 진행성 피부 편평세포암 치료제 리브타요 주사, 성인 이형접합 가족성 고콜레스테롤혈증 또는 임상적 죽상경화성 심혈관 질환 치료제 프랄런트 주사, 코로나19 치료제 리젠코브, 성인 류머티스 관절염 치료제 케브자라 용액을 공급하고 있다.
자세히 보기 Regeneron Pharmaceuticals, Inc. 기본 사항 요약 Regeneron Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? 0R2M 기본 통계 시가총액 US$72.41b 수익(TTM ) US$4.65b 수익(TTM ) US$13.85b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 0R2M 손익 계산서(TTM ) 수익 US$13.85b 수익 비용 US$6.82b 총 이익 US$7.03b 기타 비용 US$2.37b 수익 US$4.65b
주당 순이익(EPS) 43.26 총 마진 50.75% 순이익 마진 33.61% 부채/자본 비율 6.8%
0R2M 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/01 21:34 장 마감 주가 2025/01/31 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Regeneron Pharmaceuticals, Inc. 66 애널리스트 중 26 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
63 더 많은 분석가 보기 
